TY - JOUR
T1 - Monitoring immune responses in the tumor microenvironment
AU - Wargo, Jennifer A.
AU - Reddy, Sangeetha M.
AU - Reuben, Alexandre
AU - Sharma, Padmanee
N1 - Funding Information:
Jennifer Wargo acknowledges funding from the Kenedy Foundation grant 0727030 .
Funding Information:
Sangeetha Reddy was supported by the National Institutes of Health T32 training grant T32 CA009666 .
Funding Information:
Padmanee Sharma acknowledges funding from the National Institutes of Health grant R01 CA 163793 , Institutional Core Grant P30 CA016672 , CPRIT grant RP120108 , SU2C-CRI-AACR Cancer Immunotherapy Dream Team grant SU2C-AACR-DT1012 , and the PCF Immunology Challenge Grant.
Publisher Copyright:
© 2016 Elsevier Ltd.
PY - 2016/8/1
Y1 - 2016/8/1
N2 - Immune monitoring in the tumor microenvironment allows for important insights into immune mechanisms of response and resistance to various cancer treatments; however clinical challenges exist using current strategies. Significant questions remain regarding monitoring of archival versus fresh tissue, assessment of static versus dynamic markers, evaluation of limited tissue samples, and the translation of insights gained from immunologically 'hot' tumors such as melanoma to other 'cold' tumor microenvironments prevalent in other cancer types. Current and emerging immune monitoring strategies will be examined herein, and genomic-based assays complementing these techniques will also be discussed. Finally, host genomic and external environmental factors influencing anti-tumor immune responses will be considered, including the role of the gut microbiome. Though optimal immune monitoring techniques are in evolution, great promise exists in recent advances that will help guide patient selection as far as type, sequence, and combination of therapeutic regimens to enhance anti-tumor immunity and clinical responses.
AB - Immune monitoring in the tumor microenvironment allows for important insights into immune mechanisms of response and resistance to various cancer treatments; however clinical challenges exist using current strategies. Significant questions remain regarding monitoring of archival versus fresh tissue, assessment of static versus dynamic markers, evaluation of limited tissue samples, and the translation of insights gained from immunologically 'hot' tumors such as melanoma to other 'cold' tumor microenvironments prevalent in other cancer types. Current and emerging immune monitoring strategies will be examined herein, and genomic-based assays complementing these techniques will also be discussed. Finally, host genomic and external environmental factors influencing anti-tumor immune responses will be considered, including the role of the gut microbiome. Though optimal immune monitoring techniques are in evolution, great promise exists in recent advances that will help guide patient selection as far as type, sequence, and combination of therapeutic regimens to enhance anti-tumor immunity and clinical responses.
UR - http://www.scopus.com/inward/record.url?scp=84969929995&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84969929995&partnerID=8YFLogxK
U2 - 10.1016/j.coi.2016.05.006
DO - 10.1016/j.coi.2016.05.006
M3 - Review article
C2 - 27240055
AN - SCOPUS:84969929995
SN - 0952-7915
VL - 41
SP - 23
EP - 31
JO - Current Opinion in Immunology
JF - Current Opinion in Immunology
ER -